{"id":"r-combination-chemotherapy","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"20-30","effect":"Anemia"},{"rate":"15-25","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Infusion reactions"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"15-25","effect":"Infection"},{"rate":"10-20","effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab binds to CD20 antigen on B-cell surfaces, triggering antibody-dependent cellular cytotoxicity (ADCC) and direct apoptosis. The combination with chemotherapy agents (typically cyclophosphamide, doxorubicin, vincristine, and prednisone in R-CHOP regimens) provides synergistic cytotoxic effects against lymphoid malignancies. This approach enhances tumor cell death through both immunological and chemotherapeutic mechanisms.","oneSentence":"R-combination chemotherapy uses rituximab (a monoclonal antibody targeting CD20) combined with cytotoxic chemotherapy agents to kill B-cell malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:36:55.678Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma"},{"name":"Diffuse large B-cell lymphoma (DLBCL)"},{"name":"Follicular lymphoma"},{"name":"Chronic lymphocytic leukemia (CLL)"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT05768932","phase":"PHASE1","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2022-12-14","conditions":"Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer","enrollment":260},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT00428142","phase":"PHASE2","title":"Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-05-01","conditions":"Lymphoma","enrollment":95},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT06047080","phase":"PHASE3","title":"An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-18","conditions":"Large B-Cell Lymphoma","enrollment":1130},{"nctId":"NCT05735184","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2023-07-18","conditions":"Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML","enrollment":420},{"nctId":"NCT05627232","phase":"PHASE1","title":"Tazemetostat and Palbociclib With CPX-351for R/R AML","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-08-28","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT05934448","phase":"PHASE2","title":"Pembro Plus CAR T-cell Therapy in R/R in PMBCL","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-11-15","conditions":"Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory","enrollment":35},{"nctId":"NCT07444918","phase":"PHASE2","title":"Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-01","conditions":"Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)","enrollment":33},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT01013649","phase":"PHASE3","title":"Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-04-05","conditions":"Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm","enrollment":546},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT03147612","phase":"PHASE2","title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-08","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1","enrollment":22},{"nctId":"NCT07409428","phase":"PHASE3","title":"A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-10","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":240},{"nctId":"NCT07408063","phase":"PHASE2","title":"A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-02-02","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07398638","phase":"PHASE1, PHASE2","title":"Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-28","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":122},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":"Follicular Lymphoma (FL)","enrollment":733},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT06091865","phase":"PHASE3","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-13","conditions":"Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":904},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT05583149","phase":"PHASE2","title":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick C. Johnson, MD","startDate":"2023-03-01","conditions":"Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL","enrollment":28},{"nctId":"NCT07372352","phase":"PHASE2","title":"Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-15","conditions":"Peripheral T Cells Lymphoma (PTCL)","enrollment":26},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":"Multiple Myeloma","enrollment":729},{"nctId":"NCT07354984","phase":"PHASE2","title":"A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06648889","phase":"PHASE2","title":"Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Goethe University","startDate":"2024-10-22","conditions":"T-ALL","enrollment":40},{"nctId":"NCT04855253","phase":"PHASE1, PHASE2","title":"Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL","status":"SUSPENDED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2021-06-09","conditions":"DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma","enrollment":30},{"nctId":"NCT07340151","phase":"NA","title":"Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-02","conditions":"Adenocarcinoma of the Pancreas","enrollment":40},{"nctId":"NCT07098364","phase":"PHASE1, PHASE2","title":"ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-12-27","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":33},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":"Lymphoma, Follicular","enrollment":90},{"nctId":"NCT01995058","phase":"PHASE2","title":"Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC","status":"TERMINATED","sponsor":"Exelixis","startDate":"2014-02","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms","enrollment":54},{"nctId":"NCT04240002","phase":"PHASE1, PHASE2","title":"A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-09-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)","enrollment":9},{"nctId":"NCT05952037","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-10-23","conditions":"Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory","enrollment":114},{"nctId":"NCT06252753","phase":"","title":"Observational Study Protocol: LIVER-R","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-16","conditions":"Hepatobiliary Cancers","enrollment":4490},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":"Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type","enrollment":20},{"nctId":"NCT05564650","phase":"PHASE1","title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-12","conditions":"Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome","enrollment":6},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":"Follicular Lymphoma","enrollment":400},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT03907488","phase":"PHASE3","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-29","conditions":"Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma","enrollment":994},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT04908696","phase":"","title":"Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-12-01","conditions":"Glottic Carcinoma, Supraglottic Carcinoma, Subglottic Carcinoma","enrollment":1000},{"nctId":"NCT01920932","phase":"PHASE2","title":"Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-08-12","conditions":"Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma","enrollment":77},{"nctId":"NCT02390869","phase":"PHASE3","title":"Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-05","conditions":"Lymphoma, Follicular","enrollment":128},{"nctId":"NCT04010968","phase":"PHASE2","title":"Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2019-09-27","conditions":"Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy","enrollment":120},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT06929624","phase":"PHASE3","title":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-04-24","conditions":"Diffuse Large B-cell Lymphoma","enrollment":280},{"nctId":"NCT06295731","phase":"PHASE2, PHASE3","title":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2024-05-14","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":410},{"nctId":"NCT05839951","phase":"","title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-04-24","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":818},{"nctId":"NCT02337985","phase":"PHASE1","title":"Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2015-11-20","conditions":"AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma","enrollment":10},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT06376162","phase":"PHASE1","title":"Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"PedAL BCU, LLC","startDate":"2025-03-18","conditions":"Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia","enrollment":20},{"nctId":"NCT05599984","phase":"PHASE1","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-12-05","conditions":"Advanced Solid Tumors","enrollment":288},{"nctId":"NCT04679012","phase":"PHASE2","title":"Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-09-24","conditions":"Richter Syndrome, Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT04777916","phase":"","title":"Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Acute Leukemia French Association","startDate":"2022-04-14","conditions":"Acute Myeloid Leukemia (AML)","enrollment":5000},{"nctId":"NCT04833114","phase":"PHASE3","title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GWT-TUD GmbH","startDate":"2021-04-30","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":306},{"nctId":"NCT00690560","phase":"PHASE2","title":"Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-05","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT04479267","phase":"PHASE2","title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2020-08-21","conditions":"Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements","enrollment":8},{"nctId":"NCT01650701","phase":"PHASE3","title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-02","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT07181785","phase":"","title":"Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.","status":"COMPLETED","sponsor":"Andrés José Maria Ferreri","startDate":"2022-07-12","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":555},{"nctId":"NCT06621212","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-05","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":72},{"nctId":"NCT05756764","phase":"","title":"Anti-obesity Pharmacotherapy and Inflammation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2023-06-01","conditions":"Obesity","enrollment":30},{"nctId":"NCT06771674","phase":"","title":"Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Hookipa Biotech GmbH","startDate":"2024-06-05","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":662},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT06986434","phase":"EARLY_PHASE1","title":"CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2025-08-26","conditions":"Relapsed or Refractory Plasma Cell Neoplasms","enrollment":20},{"nctId":"NCT00278408","phase":"PHASE3","title":"Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2006-01-02","conditions":"Lymphoma","enrollment":700},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT05883449","phase":"PHASE2","title":"Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL","status":"TERMINATED","sponsor":"Affimed GmbH","startDate":"2023-10-10","conditions":"Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma","enrollment":25},{"nctId":"NCT03505762","phase":"PHASE2","title":"Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-07-19","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT03054896","phase":"PHASE2","title":"A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-08","conditions":"Richter Syndrome","enrollment":69},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT05156970","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2021-06-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT03496779","phase":"PHASE2","title":"Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2018-04-10","conditions":"Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma","enrollment":71},{"nctId":"NCT00878254","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2009-03-25","conditions":"Mantle-Cell Lymphoma","enrollment":25},{"nctId":"NCT02763319","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-11-28","conditions":"Diffuse Large B-cell Lymphoma","enrollment":453},{"nctId":"NCT06220097","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory","enrollment":28},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT02723331","phase":"PHASE2","title":"Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates","status":"COMPLETED","sponsor":"Academic Thoracic Oncology Medical Investigators Consortium","startDate":"2016-12-30","conditions":"Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma","enrollment":48},{"nctId":"NCT05054543","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML","status":"TERMINATED","sponsor":"Apollomics Inc.","startDate":"2021-11-17","conditions":"Relapsed/Refractory AML","enrollment":140},{"nctId":"NCT04839341","phase":"PHASE1","title":"Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients","status":"COMPLETED","sponsor":"Apollomics Inc.","startDate":"2021-02-24","conditions":"Relapsed/Refractory AML","enrollment":12},{"nctId":"NCT04282109","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)","status":"COMPLETED","sponsor":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","startDate":"2020-06-03","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":141},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT05577585","phase":"NA","title":"Ketamine in OCD: Efficacy and Effects on Stress and Cognition","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2022-10-01","conditions":"Obsessive-Compulsive Disorder, Psychiatric Disorder","enrollment":60},{"nctId":"NCT00001337","phase":"PHASE2","title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1993-05-08","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma","enrollment":348},{"nctId":"NCT03742258","phase":"PHASE1","title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2019-03-13","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":12},{"nctId":"NCT06996132","phase":"PHASE2","title":"Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-05-09","conditions":"Relapsed or Refractory Aggressive B-cell Lymphoma","enrollment":25},{"nctId":"NCT03995147","phase":"PHASE2","title":"Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-08-29","conditions":"B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell","enrollment":51},{"nctId":"NCT04082364","phase":"PHASE2, PHASE3","title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2019-09-30","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer","enrollment":82},{"nctId":"NCT06601504","phase":"PHASE2","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchmed","startDate":"2024-11-05","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":61},{"nctId":"NCT06742502","phase":"PHASE2","title":"Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-12","conditions":"Primary Mediastinal Diffuse Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT02420509","phase":"","title":"Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2015-08-27","conditions":"Cancer","enrollment":2},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT06802835","phase":"PHASE1, PHASE2","title":"EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2025-05","conditions":"Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma","enrollment":148},{"nctId":"NCT05798156","phase":"PHASE2","title":"Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2023-03-20","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"R-combination chemotherapy","genericName":"R-combination chemotherapy","companyName":"Shandong Provincial Hospital","companyId":"shandong-provincial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-combination chemotherapy uses rituximab (a monoclonal antibody targeting CD20) combined with cytotoxic chemotherapy agents to kill B-cell malignancies. Used for B-cell non-Hodgkin lymphoma, Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}